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Abstract
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) spread and infections in patients with
haematological malignancies are a serious concern especially in endemic areas. Treatment failures and delay
in appropriate therapy for CRKP infections are frequent and the mortality rate associated with CRKP bacteremia
in neutropenic haematological patients is reported about 60%.
Methods: Haematological patients harboring CRKP hospitalized between February 2012 and May 2013 in an
Italian Teaching hospital were examined. Conditions favouring CRKP spread in a haematological unit, risk factors
for bacteremia in CRKP-carriers and for CRKP bacteremia-related death were evaluated in this observational
retrospective study.
Results: CRKP was isolated in 22 patients, 14 (64%) had bacteremia. Control measures implementation, particularly
the weekly rectal screening for CRKP performed in all hospitalized patients and contact precautions for CRKP-
carriers and newly admitted patients until proved CRKP-negative, reduced significantly the CRKP spread (14 new
carriers identified of 131 screened patients vs 5 of 242 after the intervention, p = 0.001). Fifty-eight percent of
carriers developed CRKP bacteremia, and acute myeloid leukemia (AML) resulted independently associated with the
bacteremia occurrence (p = 0.02). CRKP bacteremias developed mainly during neutropenia (86%) and in CRKP-
carriers (79%). CRKP bacteremias were breakthrough in 10 cases (71%). Ten of 14 patient with CRKP bacteremias
died (71%) and all had AML. The 70% of fatal bacteremias occurred in patients not yet recognized as CRKP-carriers
and 80% were breakthrough. Initial adequate antibiotic therapy resulted the only independent factor able to
protect against death (p = 0.02).
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Conclusions: The identification of CRKP-carriers is confirmed critical to prevent CRKP spread. AML patients
colonized by CRKP resulted at high risk of CRKP-bacteremia and poor outcome and the adequacy of the initial
antibiotic therapy may be effective to improve survival. To limit the increase of resistance, the extensive use of
antibiotics active against CRKP should be avoided, but in the setting of high CRKP pressure and high-risk CRKP-
colonized haematological patients, timely empiric antibiotic combinations active against CRKP could be suggested
as treatment of febrile neutropenia.
Keywords: Carbapenem-resistant Klebsiella pneumoniae, Haematological malignancies, Neutropenia, Spread,
Bacteremia
Background
The diffusion of carbapenem-resistant Klebsiella pneumo-
niae (CRKP) [1–5] in the setting of patients with haemato-
logical malignancies undergoing intensive myelosuppressive
chemotherapy is a very worrying challenge [6–11], espe-
cially in endemic areas. The most important mechanism in
carbapenem resistance in Enterobacteriaceae is the produc-
tion of carbapenemases, primarily KPC VIM NDM and
OXA-48 types, which display remarkable geographycal
variability. KPC production is the most frequent mechanism
of resistance to carbapenems in K. pneumoniae in Italy, as
already reported in the 2011 Italian survey [4] and KPC-type
carbapenemases-producing K. pneumoniae has become en-
demic, as very recently confirmed [5]. Underlying haemato-
logical disease, intensive chemotherapy, neutropenia,
gastrointestinal mucositis and prolonged hospitalization are
all conditions favouring the CRKP spread and infections,
mainly bacteremias [6–11]. Treatment failures and delay in
appropriate therapy for CRKP infections are predictable
since the recommended empiric antibiotic treatments for fe-
brile neutropenia, both monotherapy and combinations
[12–14], in most cases contain antibiotics without in vitro
activity against CRKP. The mortality rate associated with
CRKP bacteremia in neutropenic haematological patients is
reported about 60% [6–11], and expected to remain very
high, especially in particularly vulnerable patients such as
those with acute leukemia. Notwithstanding, clinical data
about the impact of CRKP in this high-risk population are
still scant in literature. In this observational study on pa-
tients with haematological malignancies conducted over a
17-month period, we aimed to identify conditions favouring
CRKP spread in a haematological unit, assess risk factors for
bacteremia in haematological patients colonized with CRKP,
and analyse risk factors for poor outcome among haemato-
logical patients with CRKP bacteremia. We also evaluated
the impact of infection control program implementation on
new CRKP acquisitions in our Haematology Department.
Methods
All patients with haematological malignancies infected
or colonized with CRKP, hospitalized between 24
February 2012 and 31 May 2013 at the Hematology
Department of the Sapienza University of Rome, were
included in the study.
Setting
The Hematology Department, located in a four-storey build-
ing, consists in 1 Pediatric and 2 Adult Wards (Unit A and
Unit B) each with 14 beds in double-occupancy rooms, 1
Transplant Unit (5 single bedrooms), 1 Short Hospitalization
Unit (5 beds), Emergency Rooms and Day Hospital. On July
and August 2012, Unit A closed for renovations.
During the study period, each ward had its own med-
ical, nursing and ancillary staff who took care of both
CRKP-positive and negative patients, while during the
night shift the medical staff was the same for the entire
Hematology Department.
CRKP spread, surveillance and isolation precautions
For all CRKP-positive patients included in the study, the
following informations about hospitalization periods, be-
fore and after the documentation of CRKP acquisition,
were collected: a) the presence and the number of
CRKP-positive patients hospitalized in the same time; b)
the occurrence of CRKP bacteremia in other patients; c)
the occurrence of the death of a CRKP-positive patient;
d) the transfer from or to other Hospitals or Depart-
ments. Patients with a positive rectal swab screening, in
the absence of any sign or symptom of infection, were
defined as colonized by CRKP. CRKP horizontal trans-
mission during the current hospitalization was hypothe-
sized for those CRKP-positive patients who had a
negative screening at admission, or had not been
transferred from or to other Hospitals or Departments.
Before March 2012, surveillance cultures from rectum,
pharynx, genitourinary tract and nasal cavity to detect
multidrug-resistant (MDR) bacteria and fungal colonization
were usually collected in neutropenic hospitalized patients.
From March 2012, infection control measures were imple-
mented in Unit B: the screening for CRKP rectal
colonization [15, 16] was performed weekly in all hospital-
ized patients and CRKP-positive patients were kept under
contact precautions [17] in isolation rooms or cohorted in
double-occupancy rooms. From September 2012, the rectal
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screening for CRKP carriage detection was extended to all
patients hospitalized in the Hematology Department,
weekly during hospitalization, prior to admission and at
entry. Newly admitted patients not screened before
hospitalization were placed under contact precautions until
the results of surveillance cultures performed at entry were
available and proved negative. All healthcare workers re-
ceived a specific training on the relevance of CRKP and its
routes of transmission.
Patients and antibacterial therapy
Medical records of all patients harboring CRKP were
reviewed. Gender, age, underlying haematological
malignancy, chemotherapy, number of hospitalizations,
length of hospitalization and neutropenia prior to CRKP
acquisition, duration of CRKP-positive patient status
(colonized or infected) during the study period (from
the first positive microbiological result, during hospitali-
zations and out-patient condition, until the end of the
study period or the discontinuation of any chemothera-
peutic course and/or hospitalization) and previous
hospitalizations, were recorded in all CRKP-positive pa-
tients. In patients with CRKP bacteremia, length of
CRKP colonization and neutropenia before bacteremia,
neutrophil count at the onset of bacteremia, antibacter-
ial treatments (initial therapy and subsequent modifica-
tions) and outcome were also recorded.
CRKP bacteremia was defined breakthrough when
blood-coltures yelding CRKP were taken in a patient
already receiving an intravenous antibacterial therapy
initiated by at least 24 h.
An antibacterial regimen was considered adequate
when it included at least 1drug displaying in vitro activ-
ity against the CRKP isolate.
CRKP colonized patients who developed bacteremia
and those who did not, and patients with CRKP
bacteremia who died and those who did not were
compared.
Microbiological studies
The CRKP isolates studied were at least one per pa-
tient (either the first colonizing or/and the first blood
isolate identified). Species identification and MIC de-
termination were performed using BD Phoenix auto-
mated microbiology system (Becton Dickinson Italia
S.p.A Milano, Italy). MICs of imipenem, meropenem,
ertapenem, gentamicin, colistin and tigecycline were
also evaluated using Etest (BioMerieux Italia S.p.A.,
Firenze Italy) in accordance with the manufacturer’s
instructions. Results are interpreted in accordance
with the last breakpoints proposed by the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) [18].
Statistical analysis
Continuous variables were compared using Kruskal-
Wallis test. Categorical variables were compared with
Fisher’s exact test; odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated.
Forward stepwise logistic regression models were
used to assess the relative importance of the various
prognostic factors that could influence the occur-
rence of bacteremia in CRKP colonized patients
(acute leukemia and acute myeloid leukemia [AML],
intensive chemotherapy, female gender, >/=7 days
spent colonized by CRKP with <100 neuthrophils/
mmc) and the occurrence of death in patients with
CRKP bacteremia (underlying disease, intensive
chemotherapy, initial adequate therapy, neutrophils
recovery >1000/mmc within 72 h after bacteremia on-
set, patient identified as CRKP carrier at bacteremia
onset, occurrence of breakthrough bacteremia within
48 h of ongoing antibiotics).
To identify risk factors for mortality, a multivariate
analysis using Cox forward regression and calculation of
Hazard Ratios with 95% CIs was also performed. Sur-
vival curves were constructed using the Kaplan-Meier
method and were compared using the log-rank test.
Results
From 24 February 2012 to 31 May 2013, a CRKP was
isolated in 22 patients, 14 (64%) developed a CRKP
bacteremia and 8 (36%) remained as CRKP rectal
carriers.
The spread of CRKP in the Hematology Department
is chronologically described in Fig. 1. The first 18 pa-
tients who acquired CRKP (colonized or infected)
were hospitalized in Unit B, the last 3 patients in
Unit A.
The first CRKP isolate was detected on 24 February
2012 at Unit B, in the blood of an AML patient who
died from CRKP bacteremia before blood-culture re-
sults were available (during a previous hospitalization
on January 2012, the patient had been treated for a
severe ESBL-producer E.coli cellulitis with prolonged
meropenem therapy and surgical dressings performed
in another Department). All the patients who were
hospitalized in Unit B were screened for the control
of CRKP spread and 5 patients were identified as
CRKP rectal carrier (March 2012). In particular, while
the second CRKP rectal carrier identified was hospi-
talized after the death of the first CRKP-positive
patient (the positive swab was collected 1 week after
entry), the third CRKP rectal carrier identified had
been transferred from another Department on 7
February 2012, therefore the patient was hospitalized
prior to and together with the two previously de-
scribed positive patients.
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Fig. 1 Spread of CRKP in the Hematology Department during the study period (February 2012 - May 2013)
Table 1 Susceptibilities to antibiotics of the 22 K. pneumoniae isolates
Antimicrobial agent MIC range
μg/mL
MIC 50 μg/mL MIC 90 μg/mL N.(%) of isolates that were susceptible
imipenem >32 >32 >32 0
meropenem >32 >32 >32 0
ertapenem >32 >32 >32 0
colistin 0.125 to 32 0.75 24 12 (54.5)
tigecycline 0.5 to 8 2 4 6 (27.2)
gentamicin 3 to >256 8 >256 0
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Regarding Unit A, the first CRKP-positive patient was
identified on January 2013. The patient, transferred from
another Department, resulted CRKP rectal carrier at entry
and died 10 days after from the underlying haematological
disease. The second CRKP rectal carrier identified, in the
period preceding the documentation of the CRKP
colonization, was either hospitalized in the same time of
the first one either submitted to an invasive procedure in
another Department.
Surveillance of CRKP spread
From March to August 2012 (6-month period), 341 rectal
swabs for CRKP screening were collected from 131 hospi-
talized patients (90 hospitalized in Unit B) (mean: 57
swabs per month) and 14 new carriers were identified (2.3
per month, 11% of all screened patients, 16% of patients
hospitalized in Unit B). During the subsequent 9-month
period (September 2012-May 2013) after the implementa-
tion of the infection control program, 1398 rectal swabs,
104 collected prior to hospitalization, (mean:155 swabs
per month) identified 5 new CRKP carriers among 242
patients screened (0.6 per month, 2% of all screened
patients) (14 new CRKP carriers of 131 screened patients
vs 5 of 242, p = 0.001).
The susceptibilities to antibiotics of the 22 K. pneumoniae
isolates are shown in Table 1.
Characteristics of patients harboring a CRKP and possible
route of CRKP acquisition
The characteristics of the 22 CRKP-positive patients are
described in Table 2. CRKP was first isolated as a rectal
colonizer without any infection sign or symptom in 19
(86%) patients, while in 3 (14%) CRKP was first isolated
in the blood.
Seventeen patients (77%) experienced only one
hospitalization as CRKP positive patients: 12 patients
died during the hospitalization (10 AML patients for




Male gender 13 59
Age (years), mean (range) 53.7
(28–76)
N° of patients who developed CRKP bacteremia 14 64
- Previously identified as CRKP rectal carriers 11
N° of patients who remained CRKP rectal carriers 8 36
UNDERLYING HAEMATOLOGIC MALIGNANCY
Acute leukemia 16 73
- Acute myeloid leukemia 12 55
Other haematologic malignancy 6 27
CHEMOTHERAPEUTIC TREATMENT 20 91
Intensive remission induction/reinduction 8 40
Intensive remission consolidation 4 20
Other chemotherapy 8 40
CHARACTERISTICS OF PATIENTS AT CRKP ACQUISITION
(n° of patients)
Rectum as first site of CRKP isolation 19 86
Blood as first site of CRKP isolation 3 14
Ongoing fluoroquinolones oral prophylaxis 11 50
Ongoing systemic antibacterial treatment
(carbapenem)
9 (1) 41
Carbapenems within the last 4 weeks 5 23
<1000 neutrophils/mm3 12 55
<100 neutrophils /mm3 10 45
days with < 1000 neutrophils/mm3 before CRKP
acquisition: mean, median (range),
19.2,13
(2–53)
days with < 100 neutrophils /mm3 before CRKP
acquisition: mean, median (range)
10.2, 4.5,
(1-53)
N° of patients negative at CRKP rectal screening
performed at entry:
19 86
First hospitalization (n° of patients) 14 64
Transferred from other Departments 2
Prior hospitalization (n° of patients) 5 23
During the period preceding CRKP acquisition:




n°of patients hospitalized together with other CRKP-
positive patients
17/19
n°of patients hospitalized together with 4 or more
CRKP carriers
11/19 86
n°of patients hospitalized together with 9 or more
CRKP carriers
6/19 64
n°of patients hospitalized when clinical emergencies
occurred in other CRKP-positive patients a
14/19
CRKP bacteremia occurrence 14/19
Table 2 Characteristics of the 22 patients harbouring
carbapenem-resistant K. pneumoniae (Continued)
death for any cause in at least 1 CRKP-positive
patients
10/19
n° of patients temporary transferred to other
Departments for invasive procedures
4/19




Transferred from other Departments
(n° of patients)
2
In the same Unit 1
a5 patients had the first CRKP-positive rectal sample collected the same day in
which a CRKP bacteremia and/or the death of a CRKP-positive patient occurred
in the ward were they were hospitalized
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CRKP bacteremia and 2 patients for causes not related to
CRKP) and 5 completed the chemotherapy program and
in the subsequent study period, they have not been hospi-
talized. Five patients (23%) experienced more hospitaliza-
tions as CRKP-positive patient (mean 5, median 4, range
3–8, hospitalizations per patient).
Overall, in the 22 patients the median duration of
CRKP-positive patient condition (colonized or infected)
was 12 days (mean 70.7 days, range 2–440 days). The 10
AML patients who developed a fatal CRKP bacteremia,
spent a mean of 11.6 days (median 5, range 3–48 days)
as CRKP-positive patient. Seven patients who have con-
cluded the chemotherapy program before the end of the
study spent a mean of 50.1 days (median 24, range 4–
162) as CRKP-positive patient, while 3 patients remained
CRKP carriers until the end of the study survey (mean
358 days, median 322, range 314–440).
Nineteen patients (86%) were negative at hospital ad-
mission (14 were hospitalized for the first time; 5 had
been previously hospitalized, 4 in the same Unit) and
data regarding the hospitalization period preceding the
CRKP acquisition (colonization or bacteremia) are
shown in Table 2. Seventeen (89%) patients were hospi-
talized at the same time of other CRKP-positive patients
(11 together with 4 or more CRKP-positive patients), 14
(74%) when a CRKP bacteremia developed in other
patients, 10 (53%) when one or more CRKP-positive pa-
tient died (notably 8 patients resulted new CRKP carriers
within 3 days following bacteremia or death occurrence).
As additional potential risk factor for CRKP acquisition,
4 of the 19 patients who were negative at admission, had
been temporarily transferred to other Departments for
invasive procedures (Table 2).
Only 3 of the 22 CRKP-positive patients (14%) resulted
CRKP carriers at entry, and all of them had been previ-
ously hospitalized. Overall, the possible acquisition of a
CRKP outside the Hematology Department (previous
hospitalization, transfer from other Departments, tem-
porary transfer to other Departments) could be assumed
in 7 out of 22 patients (32%) (Table 2).
Characteristics and risk factors for CRKP bacteremia in
colonized patients
Eleven out of 19 (58%) CRKP rectal carriers developed
CRKP bacteremia after a median of 6 days (mean
38.5 days, range 1–180) from the first CRKP-positive
rectal swab. Among these, 5 patients who had previously
been screened negative, resulted CRKP carriers only
after the onset of chemotherapy-related neutropenia and
fluoroquinolone prophylaxis initiation, and they devel-
oped the CRKP bacteremia within 48 h from the collec-
tion of the first CRKP-positive swab.
CRKP colonized patients who developed bacteremia,
and those who did not are compared in Table 3. At the
forward stepwise logistic regression model, only AML
status resulted an independent risk factor for the occur-
rence of bacteremia in colonized patients (Table 4).
CRKP bacteremias and risk factors for death
During the 17-month study period, CRKP caused 14
bacteremias, which represented the 12.5% of all Gram-
Table 3 Risk factors for bacteremia in the 19 patients colonized





N° of CRKP colonized patients 11 8
Male 5 (45%) 8 (100%)
Female 6 (54%) 0 0.01
Underlying disease
Acute leukemia 10 (91%) 3 (37.5%) 0.0075
Acute myeloid leukemia 9 (82%) 0 0.0007
Other haematological malignancy 1 (9%) 5 (62.5%) ns
Chemotherapy 7 (64%) 5 (62.5%) ns
- Intensive induction chemotherapy 6 (54%) 0 0.01
n° of patients with <1000 neutrophils/
mm3 at CRKP acquisition
5 (45%) 4 (50%) ns
n° of patients with <100 neutrophils/
mm3 at CRKP acquisition
4 (36%) 3 (37%) ns
Days spent colonized by CRKP with:














Rectal colonization 11 (100%) 8 (100%) ns
Single site colonization 4 (36%) 5 (62.5%) ns
Multiple sites colonization 7 (64%) 3 (37%) ns
Colonized sites besides the rectum
vagina/urethra 3 0
urinary tract 5 2
oral cavity, pharynx 2 2
Mucositis 6 (54%) 3 (37%) ns
- Diarrea 6 3
CRKP localized infection 7 (64%) 3 (37.5%) ns
vaginitis 3 0 ns
typhlitis 2 1
hemorroidal cellulitis 2 1
cellulitis 0 1
Previous febrile neutropenia during
CRKP colonization
6 3 ns
Previous bacteremia other than CRKP
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negative bacteremias diagnosed in patients attending the
Hematology Department. In particular, the incidence of
CRKP among all gram-negative bacteremia documented
in AML patients was 30% (9/30) compared with 5% (5/
96) in the other haematological patients (p = 0.0007).
The characteristics of patients with CRKP bacteremia
are shown in Table 5. The majority of patients had acute
leukemia (93%), mostly AML (86%), were neutropenic
(86%) and were CRKP rectal carriers (79%). Eleven
patients (79%) developed CRKP bacteremia during the
first hospitalization as CRKP-positive patient. CRKP
bacteremia was breakthrough in 10 cases (71%) develop-
ing in patients already receiving an empiric intravenous
treatment for febrile neutropenia, initiated by 48 h or
less in 7 cases (43%). The ongoing antibiotics were
piperacillin-tazobactam in 5 cases, piperacillin-
tazobactam plus tigecycline in 2, meropenem in 2, ceftri-
axone in 1.
Overall, 64% (9 of 14) of patients with CRKP
bacteremia received as initial or subsequently modified
treatment, at least 1 drug in vitro active against the
CRKP isolate (Table 5).
At the onset of CRKP bacteremia, 8 patients (57%)
did not receive any antibiotic in vitro active against
CRKP while 6 patients (43%) were initially treated
with at least 1 drug active against CRKP. Of these, 3
were recognized as CRKP-carriers and were receiving
empiric antibiotic treatment, the sudden onset of
shock and high fever led to the rapid change of the
ongoing treatment according to the in vitro suscepti-
bility of the colonizing CRKP isolate and blood
cultures proved CRKP breakthrough bacteremia oc-
currence in all the cases.
Overall, 12 of the 22 (55%) patients infected or colo-
nized by CRKP died: 10 of CRKP bacteremia (45%), 1 of
MDR Acinetobacter baumannii bacteremia and 1 of the
underlying haematological malignancy.
CRKP bacteremias were fatal in 71.4% of cases (10/14),
all fatal bacteremia occurred in AML patients and
during the first hospitalization as CRKP-positive patient,
and the 50% of patients died within 72–96 h from
bacteremia onset (Table 5). Patients with CRKP
bacteremia who died and those who survived are com-
pared in Table 6. In particular, the rates of patients colo-
nized, and of those colonized at single (rectum) or
multiple body sites, were similar in survivors and non-
survivors. However, all the 7 patients who had not been
identified as CRKP carriers at the onset of bacteremia (1
not screened, 2 true negative and 4 without the results
of the first CRKP positive rectal screening available yet)
died for bacteremia, and 6 had received an inadequate
initial treatment.
Mainly because of the limited sample size, no risk
factors for mortality could be included in the for-
ward stepwise logistic regression model. In the Cox
regression calculation (Table 7) only the initial ad-
equate antibiotic therapy resulted an independent
factor able to protect against 30-days mortality.
Kaplan-Meier curves confirmed that patients treated
with initial adequate antibiotic therapy had higher
30 days survival rates, if compared to those initially
treated with inadequate therapy (log rank test =9.17;
p = 0.002) (Fig. 2).
Discussion
The implementation of control measures to limit the
spread of CRKP, particularly the careful weekly screening
of CRKP rectal colonization aimed to the prompt
identification of CRKP positive patients, together with
the isolation procedures extended to newly admitted
Table 4 Forward stepwise logistic regression model of risk factors for bacteremia in carbapenem-resistant K. pneumoniae (CRKP)
colonized patients
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patients still not screened, proved effective. After the
intervention, the rate of new CRKP-positive among
hospitalized patients decreased from 11 to 2%, from
2.3 to 0.8 new CRKP-positive patient per month.
The detection of the 45% of CRKP-positive patients
during the 3-month period of bed shortage, when
the urgency of hospitalization might have reduced
the accuracy of isolation procedures - particularly
for not screened newly admitted patients - corrobo-
rates this result.
Even if not confirmed by genotyping analysis of the
CRKP isolates, it is possible that the failure to recognize
the first CRKP carrier might have been responsible of
the CRKP spread in the Hematology Department, stres-
sing further the importance of the CRKP carriers
identification, especially in the setting of high-risk haem-
atologic patient.
The high colonization pressure favors CRKP diffusion
[19–21]. The workload due to the concomitant
hospitalization of a high number of CRKP carriers kept
under contact precaution may increase the risk of isola-
tion precaution transgressions [20, 21]. Moreover, in our
experience, the occurrence of clinical emergencies in
CRKP-positive patients seems to have further facilitated
and accelerated the spread within the Unit: in the major-
ity of patients we documented the CRKP acquisition
after the occurrence of CRKP bacteremias or deaths in
the Unit where they were hospitalized, and in 42% of
cases within the following 3 days. Patient admissions or
temporary transfer and readmissions from other wards
where they could acquire CRKP may further increase
colonization pressure [20, 21]. This might have hap-
pened in 27% of our cases, frustrating the efforts made
to prevent CRKP spread and, in our opinion, also
Table 5 Carbapenem-resistant K. pneumoniae
bacteremias
N° %
N° of cases 14
Mean age, years (range) 51.5
(28–68)
Male/female 5/9
Acute leukemia 13 93
Acute myeloid leukemia 12 86
Other haematologic malignancy 1 7
Intensive Induction /reinduction chemotherapy 6 54
Intensive consolidation chemotherapy 4 29




No CRKP rectal carriers (n° of patients) 3 21
CRKP rectal carriers (n° of patients) 11 79
CRKP carrier from≤ 2 days (n° of patients) 5 36




Multiple-sites CRKP colonization 6 54
CRKP colonization acquired in the current hospitalization 8 57
CRKP colonization acquired during a previous
hospitalization
3 21
Documented source of bacteremia 7 50
labia and vaginal cellulitis 3 21
hemorroidal cellulitis 1 7
typhlitis 2 14
lung 1 7
Bacteremia of unknown origin (CRKP carriers) 7 (4) 50
Previous antibiotic treatment 13 93
Piperacillin-tazobactam monotherapy 11 79
Tigecyclin containing combination 8 57
Carbapenem containing combination 3 21
N° of patients with <1000 neutrophils/mmc at the onset
of bacteremia
12 86




Persistent bacteremia (≥3 days) 9 64
- days of bacteremia, mean (range) 4.6
(3–10)
Breakthrough bacteremia 10 71
- days of antibiotic treatment before CRKP bacteremia
onset: mean, median (range)
3.6, 2
(1–10)
Overall (initial or subsequently modified) adequatea
antibiotic treatment
9 64
Initial adequate antibiotic treatment 6b 43
One “in vitro” active antibiotic 5c 36
More than 1 in vitro active antibiotics 1d 7
Table 5 Carbapenem-resistant K. pneumoniae
bacteremias (Continued)
Response to adequate initial treatment 2 14
Initial inadequate antibiotic treatment 8e 57
Modification of inadequate initial treatment (within 48 h) 7 (6) 50
Modification with adequate antibiotics 3 21
Response to antibiotic treatment modification 0
Deaths 10 71
Mean days for death (range) 4.6
(2–12)
-
Early death (within 72–96 h) 5 36
Shock 7 50
Breakthrough bacteremia 8 57
aThe antibacterial regimen included at least 1 drug displaying in vitro activity
against the CRKP isolate
bThe CRKP bacteremia was breakthrough in 3 cases
ccolistin in 1 case, tigecyclin in 4 cases
dcolistin + tigecycline
eThe CRKP bacteremia was breakthrough in 7 cases
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suggesting strict caution in the management of patients
outside controlled wards.
Colonization was detected during neutropenia in half
of the patients. We observed that the 26% of carriers
had proved negative at the initial screening for CRKP
carriage, and had the first CRKP positive swab collected
after the onset of profound neutropenia and the initi-
ation of fluoroquinololone prophylaxis, highlighting the
role of timing and frequency of rectal controls. The rate
(58%) of rectal carriers who developed bacteremia re-
sulted much higher than the 39% reported in haemato-
logical patients in a multicentre prospective study [22],
and the 26 and 40% reported in auto- and allo-stem cell
transplant recipients, respectively [11]. This difference
may be explained both by the high frequency of screen-
ings - which prevented the possible underestimation of
CRKP-carriers rate - and the high-risk level of our colo-
nized population who were mainly acute leukemia pa-
tients (68%), AML in the 54% of cases. In our study, all
the 9 AML patients who were CRKP carriers developed
CRKP bacteremia, and the AML status was the only in-
dependent risk factor identified in CRKP carriers for
bacteremia. We believe that the only strategy to reduce
the incidence of CRKP bacteremias is to decrease the
Table 6 Risk factors for death in patients with carbapenem-
resistant K. pneumoniae bacteremia at univariate analysis
survivors nonsurvivors p
N° of patients 4 (29%) 10 (71%)





male 2 3 ns
female 2 7
Acute myeloid leukemia 2 (50%) 10 (100%) 0.06
Induction/reinduction intensive chemotherapy 0 6 (60%) 0.08
Steroids 4 (100%) 10 (100%) ns
Neutrophils count at the onset of bacteremia (n° of patients)
< 1000 neutrophils/mmc 3 (75%) 9 (90%) ns
< 100 neutrophils /mmc 3 (75%) 8 (80%) ns
days of neutropenia before bacteremia, mean, median (range)










Neutrophil recovery (>1000/mmc) within 72 h
from the onset of bacteremia (n° of pts)
3 (75%) 0 0.004
CRKP rectal carrier 4 (100%) 7 (70%) ns
One-site colonization 2 (50%) 4 (40%) ns
Multiple-sites colonization 2 (50%) 3 (30%) ns
No CRKP rectal carrier 0 3 (30%) ns
Patients not identified as CRKP carriers at the
onset of bacteremia
0 7a (70%) 0.06
Documented source of bacteremia 2 (50%) 5 (50%) ns
Fever of unknown origin 2 (50%) 5 (50%) ns
CRKP carrier 2 (50%) 2 (20%) ns
Breakthrough bacteremia 2 (50%) 8 (80%) ns
occurrence within 48 h of ongoing antibiotics 0 6 (60%) 0.08
Persistent bacteremia (≥3 days) 2 (50%) 7 (70%) ns





Shock 2 (50%) 6 (60%) ns
Overall adequate antibiotic therapyb 4 (100%) 5 (50%) ns
Initial adequate antibiotic therapyb 4c
(100%)
2d (20%) 0.001
Modification of the initial antibiotic therapy 2e (20%) 7f (70%) ns
- with adequate antibiotic therapyb 2 3 ns
in vitro colistin-resistant CRKP isolate 1 6 ns
in vitro colistin - and tigecycline resistant CRKP
isolate
0 5 ns
in vitro colistin-, tigecyclin- and gentamycin-
resistant CRKP isolate
1 5 ns
a1 patient was not screened, 2 resulted negative, in 4 patients the first positive
result was not available
bThe antibacterial regimen included at least 1 drug displaying in vitro activity
against the CRKP isolate
ctigecyclin in 3 cases, colistin in 1 case
dtigecyclin and tigecyclin + colistin combination in 1 case each
ecolistin and colistin + gentamicin combination in 1 case each
ftigecycline in 2 cases, tigecycline +meropenem combination in 2 cases,
colistin + gentamicin + tigecycline combination in 3 cases
Table 7 Multivariate models of risk factors for 30-day crude
mortality in patients with carbapenem-resistant K.pneumoniae
bacteremia
HR (95% CI) p
Model1
• Initial adequate therapy 0.08 (0.01 to 0.72) 0.02
• Pt not identified as CRKP carrier at
onset
Not included in the model
• Neutrophil recovery (>1000/
mmc) within 72 h from the
onset of bacteremia
Not included in the model
Model2
• Initial adequate therapy 0.08 (0.01 to 0.72) 0.02
• Breakthrough bacteremia
occurrence within 48 h of
ongoing antibiotics
0.17 (0.01 to 2.58) 0.20
• Intensive Chemotherapy 10.9 (0.73 to 162.8) 0.08
• AML Not included in the model
Model3
• Initial adequate therapy 0.05 (0.002 to 0.86) 0.04
• Breakthrough bacteremia
occurrence within 48 h
of ongoing antibiotics
0.17 (0.01 to 2.58) 0.20
• Intensive Chemotherapy 10.9 (0.73 to 162.8) 0.08
• Pt not identified as CRKP carrier
at onset
Not included in the model
• Neutrophil recovery (>1000/
mmc) within 72 h
from the onset of bacteremia
Not included in the model
• AML Not included in the model
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number of AML patients who are CRKP carriers, with
active control measures against CRKP spread.
Overall, 45% of all patients harbouring CRKP and 37%
of CRKP rectal carriers died of CRKP bacteremia. We
found a higher mortality rate of CRKP bacteremia (71.4,
36% within 72–96 h) if compared to the 57.6% (8) and
53% (10) reported in haematological patients. This could
be related, also in this circumstance, to the higher risk of
our patients who developed bacteremia, of which 93%
had acute leukemia, 86% AML, compared with 54% (8)
and 57% (10) AML patients with CRKP bacteremia re-
ported. All the patients who died for CRKP bacteremia
had AML (they represented the 83% of AML patients
who developed CRKP bacteremia) and all died for CRKP
bacteremia during the first hospitalization as CRKP-
positive patients (7 had become CRKP colonized and 3
developed the bacteremia without any previous micro-
biological evidence of CRKP colonization).
As already described in haematological patients [8, 10,
11], the majority (86%) of CRKP bacteremias occurred
during neutropenia but, unlike other experiences [10],
the 71.4% of bacteremias developed in patients already
receiving an antibacterial therapy without in vitro activ-
ity against CRKP, and the 80% of these CRKP break-
through bacteremias were fatal.
Even if CRKP bacteremias are usually preceded by rec-
tal colonization [10, 11, 22], in our analysis previous
CRKP colonization did not result as a risk factor for
bacteremia, while AML did. In particular, we noted that
in neutropenic patients colonization may rapidly pro-
gress in bacteremia, and bacteremia can develop before
the detection of CRKP colonization or the availability of
positive microbiological results. In our experience, des-
pite the weekly CRKP rectal screening, 50% of all CRKP
bacteremias and 70% of fatal CRKP bacteremias devel-
oped in patients not recognized as CRKP carriers, fur-
ther reducing the possibility of an initial appropriate
treatment. This may have contributed, together with the
high rate of CRKP breakthrough bacteremias - of which
80% fatal - and with the initial lack of experience, to the
delay in active drug administration and the high mortal-
ity rate of CRKP bacteremias.
The optimal treatment of infections caused by CRKP
is still not defined [7, 23–25]. To improve survival in
bacteremias a combined treatment with 2 or more in
vitro active drugs (e.g.,polymixins, tigecycline, fosfomy-
cin, gentamicin), including also carbapenems, is sug-
gested [23–31], particularly as initial treatment [11, 23]
and in high risk patients [9, 11, 24, 25]. To reduce the
delay in adequate treatment of CRKP infection and the
mortality rate, antibiotic combinations active against
CRKP are suggested as empiric treatment of febrile neu-
tropenia in CRKP colonized haematological patients
[11]. In our experience, the initial adequate antibiotic
therapy resulted the only condition able to protect
against death and, like in other studies [9, 10], a very
low rate of fatal CRKP bacteremias (20%) received active
drugs as initial treatment. The emergence of antibiotic
resistance is however a primary concern [26–31] and to
avoid its fearsome increase, we believe that the extensive
use of antibiotics active against CRKP for empiric treat-
ments, or even more for the eradication of CRKP car-
riage [32–34] should be cautious and thoughtful also in
CRKP endemicity, as in our country. The susceptibility
profile of our CRKP isolates highlights the limited thera-
peutic options available and, in agreement with other re-
ports [35], we observed the 86% of mortality in colistin-
resistant CRKP bacteremia.
Fig. 2 Kaplan–Meier curves showing the impact of initial adequate antibiotic therapy on survival at 30 days in patients with CRKP bacteremia (log
rank test =9.17, p = 0.002)
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The low number of patients included in the study,
the monocentric design and the lack of genotyping
analysis of the CRKP isolates represent a limitation of
the present analysis, however the study provides con-
sistent data about the clinical impact of CRKP spread
and CRKP infections in patients with haematological
malignancies.
Conclusions
The careful identification of carriers is confirmed critical to
prevent the spread of CRKP also in haematological patients.
Colonized AML patients resulted at high risk of CRKP
bacteremia and poor outcome, and the initial therapy with
active antibiotics may be effective to improve survival.
Thus, in the setting of high CRKP pressure and high-risk
haematological patients colonized by CRKP, particularly
AML patients, the occurrence of a CRKP bacteremia
should be strongly suspected in case of febrile neutropenia
and timely empiric administration of combinations active
against CRKP could be appropriate. We are currently con-
ducting a prospective study to better define which haem-
atological patients may benefit from this strategy.
Abbreviation
AML: Acute myeloid leukemia; CRKP: Carbapenem-resistant Klebsiella
pneumoniae; MDR: Multidrug-resistant
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